Pancreatic Cancer Research

ResearcherKaohsiung Medical UniversityActive in the last 2 years

Yung‐Yeh Su

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5133-5316; OpenAlex author ID A5058700958, A5109141354, A5135323533. Sources: OpenAlex.

Their work

Papers
26 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2020: 3 papers · 2021: 1 paper · 2022: 8 papers · 2023: 4 papers · 2024: 3 papers · 2025: 2 papers · 2026: 5 papers

Papers 26

  1. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). First author DOI 10.1016/j.ejca.2026.116229↗
  2. Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort. Co-author DOI 10.1016/j.jfma.2026.04.039↗
  3. Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort… Co-author DOI 10.1016/j.jfma.2026.05.008↗
  4. A decade of progress: a before and after study on improved survival in pancreatic cancer through evolving multimodal therapy. Co-author DOI 10.1097/js9.0000000000005024↗
  5. A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC. Last author DOI 10.1158/1078-0432.ccr-25-4564↗
  6. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  7. Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells. Co-author DOI 10.1186/s12943-024-02207-4↗
  8. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Co-author DOI 10.1016/j.bj.2023.100696↗
  9. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.014↗
  10. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan. First author DOI 10.1186/s12929-024-01008-7↗
  11. Investigation into the content of red material in EUS-guided pancreatic cancer biopsies. First author DOI 10.1016/j.gie.2023.01.041↗
  12. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study. Co-author DOI 10.1097/js9.0000000000000495↗
  13. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers15041008↗
  14. Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination. Co-author PMID 37693128↗
  15. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… Co-author DOI 10.1002/jhbp.1128↗
  16. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative On… Co-author DOI 10.1038/s41416-021-01649-7↗
  17. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Co-author DOI 10.3389/fonc.2022.800842↗
  18. Semaphorin 6C Suppresses Proliferation of Pancreatic Cancer Cells via Inhibition of the AKT/GSK3/β-Catenin/Cyclin D1 Pathway. Co-author DOI 10.3390/ijms23052608↗
  19. Clustering of Chromatin Remodeling Enzymes Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Pancreatic Cancer. Co-author DOI 10.7150/ijms.73800↗
  20. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Co-author PMID 35530292↗
  21. Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience. Co-author PMID 35693078↗
  22. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic duc… Co-author PMID 36504882↗
  23. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. First author DOI 10.1177/17588359211058255↗
  24. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Co-author DOI 10.1038/s41598-020-64421-6↗
  25. Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Co-author DOI 10.1038/s41598-020-77250-4↗
  26. Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-cente… Co-author DOI 10.1371/journal.pone.0244487↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yan‐Shen Shan · 20 shared papers, 2020–2026 · strength 3.33
  2. Li‐Tzong Chen · 19 shared papers, 2020–2026 · strength 2.96
  3. Nai‐Jung Chiang · 18 shared papers, 2020–2026 · strength 2.79
  4. Li‐Yuan Bai · 13 shared papers, 2020–2026 · strength 2.17
  5. Chung‐Pin Li · 12 shared papers, 2021–2026 · strength 2.02
  6. Tai‐Jan Chiu · 11 shared papers, 2021–2026 · strength 1.87
  7. Wen‐Chi Chou · 11 shared papers, 2021–2026 · strength 1.80
  8. Shih‐Hung Yang · 11 shared papers, 2021–2026 · strength 1.77
  9. Jen‐Shi Chen · 9 shared papers, 2021–2026 · strength 1.37
  10. Yen‐Yang Chen · 8 shared papers, 2021–2024 · strength 1.12
  11. Cheng‐Ming Peng · 7 shared papers, 2021–2024 · strength 0.93
  12. Chien‐Jui Huang · 5 shared papers, 2022–2024 · strength 0.88
  13. Ya‐Chin Hou · 4 shared papers, 2022–2026 · strength 0.81
  14. Hui‐Jen Tsai · 5 shared papers, 2020–2026 · strength 0.80
  15. I‐Wei Ho · 3 shared papers, 2026 · strength 0.75
  16. Ying‐Jui Chao · 4 shared papers, 2022–2026 · strength 0.70
  17. Siao Muk Cheng · 3 shared papers, 2024–2026 · strength 0.63
  18. Ping‐Jui Su · 3 shared papers, 2022–2026 · strength 0.57
  19. Ting‐Kai Liao · 3 shared papers, 2022–2026 · strength 0.57
  20. Hsiu-Tzu Wang · 2 shared papers, 2026 · strength 0.50
  21. Yu‐Hsuan Hung · 2 shared papers, 2022–2023 · strength 0.35
  22. Wen‐Chun Hung · 2 shared papers, 2022–2023 · strength 0.35
  23. Hui‐Ching Wang · 2 shared papers, 2020–2022 · strength 0.26
  24. Kun‐Ming Rau · 1 shared paper, 2026 · strength 0.25
  25. Yao‐Yu Hsieh · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.